PTCSC3 is involved in papillary thyroid carcinoma development by modulating S100A4 gene expression

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 10, 2015, Pages E1370-E1377

  Jendrzejewski, Jaroslaw ^a,b   Thomas, Andrew ^a   Liyanarachchi, Sandya ^a   Eiterman, Andrew ^a   Tomsic, Jerneja ^a   He, Huiling ^a   Radomska, Hanna S ^a   Li, Wei ^a   Nagy, Rebecca ^a   Sworczak, Krzysztof ^b   De La Chapelle, Albert ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; VASCULOTROPIN; CALVASCULIN; PROTEIN S 100; PTCSC3 UNTRANSLATED RNA, HUMAN; S100A4 PROTEIN, HUMAN; UNTRANSLATED RNA; VASCULOTROPIN A;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE TARGETING; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MMP 9 GENE; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PTCSC3 GENE; S100A4 GENE; THYROID CARCINOMA; THYROID GLAND TISSUE; TUMOR INVASION; UPREGULATION; VEGF GENE; WESTERN BLOTTING; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; PAPILLARY CARCINOMA; PATHOLOGY; THYROID GLAND; THYROID TUMOR; TUMOR CELL LINE;

CARCINOGENESIS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; RNA, UNTRANSLATED; S100 CALCIUM-BINDING PROTEIN A4; S100 PROTEINS; THYROID GLAND; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84943759178     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2247     Document Type: Article

References (36)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index.
2. Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:2338-2366.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
4. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer. 1997;80:1529-1537.
5. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375-379.
6. Jones AM, Howarth KM, Martin L, et al. Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24. J Med Genet. 2012;49:158-163.
7. Gudmundsson J, Sulem P, Gudbjartsson DF, et al.Commonvariants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet. 2009;41:460-464.
8. Matsuse M, Takahashi M, Mitsutake N, et al. The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population. J Med Genet. 2011;48:645-648.
9. WangYL, Feng SH,GuoSC, et al. Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population. J Med Genet. 2013;50:689-695.
10. Rogounovitch T, Bychkov A, Takahashi M, et al. The common genetic variant rs944289 at chromosome 14q13.3 associates with risk of both malignant and benign thyroid tumors in Japanese population. Thyroid. 2015;25:333-340.
11. Jendrzejewski J, He H, Radomska HS, et al. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci U S A. 2012;109:8646-8651.
12. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2005;102: 19075-19080.
13. Jia W, Gao XJ, Zhang ZD, Yang ZX, Zhang G. S100A4 silencing suppresses proliferation, angiogenesis and invasion of thyroid cancer cells through downregulation of MMP-9 and VEGF. Eur Rev Med Pharmacol Sci. 2013;17:1495-1508.
14. Donato R. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33:637-668.
15. Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J Cancer Res. 2014;4:89-115.
16. Rosty C, Ueki T, Argani P, et al. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation andDNA hypomethylation. Am J Pathol. 2002;160:45-50.
17. Yonemura Y, Endou Y, Kimura K, et al. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res. 2000;6:4234-4242.
18. Davies BR, O'Donnell M, Durkan GC, et al. Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol. 2002;196:292-299.
19. Lee WY, Su WC, Lin PW, Guo HR, Chang TW, Chen HH. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Oncology. 2004;66: 429-438.
20. Maelandsmo GM, Hovig E, Skrede M, et al. Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res. 1996;56:5490-5498.
21. Ambartsumian NS, Grigorian MS, Larsen IF, et al. Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene. 1996;13:1621-1630.
22. Grum-Schwensen B, Klingelhofer J, Berg CH, et al. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. 2005;65:3772-3780.
23. Zou M, Famulski KS, Parhar RS, et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab. 2004; 89:6146-6154.
24. Zou M, Al-Baradie RS, Al-Hindi H, Farid NR, Shi Y. S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer. 2005;93:1277-1284.
25. Rogounovitch TI, Bychkov A, Takahashi M, et al. The common genetic variant rs944289 on chromosome 14q13.3 associates with risk of both malignant and benign thyroid tumors in the Japanese population. Thyroid. 2015;25:333-340.
26. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Discovery of common variants associated with lowTSHlevels and thyroid cancer risk. Nat Genet. 2012;44:319-322.
27. Donato R, Cannon BR, Sorci G, et al. Functions of S100 proteins. Curr Mol Med. 2013;13:24-57.
28. Shen XH, Qi P, Du X. Long non-coding RNAs in cancer invasion and metastasis. Mod Pathol. 2015;28:4-13.
29. Liu H, Radisky DC, Nelson CM, et al. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci USA. 2006;103:4134-4139.
30. Yang L, Han Y, Suarez Saiz F, MindenMD.Atumor suppressor and oncogene: The WT1 story. Leukemia. 2007;21:868-876.
31. Liu H, Radisky DC, Yang D, et al. MYC suppresses cancer metastasis by direct transcriptional silencing of alphav and beta3 integrin subunits. Nat Cell Biol. 2012;14:567-574.
32. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010;24:1580-1589.
33. Ordonez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol. 2000;7:123-127.
34. Kwei KA, Kim YH, Girard L, et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene. 2008;27:3635-3640.
35. Winslow MM, Dayton TL, Verhaak RG, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 2011;473:101-104.
36. Maeda Y, Tsuchiya T, Hao H, et al. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. J Clin Invest. 2012;122:4388-4400.